CPhI Worldwide has announced the opening of the annual Pharma Awards for 2016 – with four new categories added
Now in their 13th consecutive year, the CPhI Pharma Awards will honour companies and individuals driving the pharma industry forward through innovations, new approaches, technologies and strategies.
This year’s awards are open to applications from across the pharmaceutical industry and are split into 12 categories, four more categories than in 2015, in an effort to accommodate the increased demand from companies across the pharma supply chain.
In 2015, CPhI reported a 100% increase in entries and CPhI is expecting even more interest in 2016.
Following the trends in the market, and the growth in APIs and excipients, this category has now been split into two separate awards: ‘Excellence in API Development’ and ‘Excellence in Formulation and Excipients’.
A new category is also being created to acknowledge achievements in drug delivery devices: ‘Excellence in Pharma: Drug Delivery Devices’.
Additional new categories include ‘Excellence in Pharma: Regulatory Procedures and Compliance’, ‘Excellence in Pharma: Analysis, Testing and Quality Control’, and ‘Excellence in Pharma: Corporate Social Responsibility’.
Entries are free of charge and the submission deadline is the 14th August 2016 – no entries submitted after this date will be valid for consideration – with finalists to be announced in September.
Andreas Mavrommatis, marketing director pharma, UBM EMEA said: “We are excited to enter the 13th year of recognising innovation and thought leadership in the pharma industry and this year we have opened up four new categories to ensure we fully cover the breadth of exceptional applications.
“In 2015, we had an extraordinary, record-breaking number of entries, growing 100% from 2014 – this year we expect the number to rise still further.
“The CPhI Pharma Awards provide an excellent platform for honouring individuals and companies who push the boundaries to develop solutions to the industry’s most pressing needs.
“The new categories give us the scope to recognise the best in pharma.”